GlassScriptPhysician profile
Evgueni Roudachevski
NPI 1215993787
$3,025.34
in general payments reported to CMS, 2019-2025
30 companies · $592 in 2025
The $592 reported for 2025 was more than what 81% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $478 · 2021: $391 · 2022: $341 · 2023: $497 · 2024: $321 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.57 |
| Education | $116.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $546.43 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Novartis Pharmaceuticals Corporation | $504.09 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $260.98 | 2020-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $214.10 | 2024-2025 | Airsupra, Breztri |
| Sunovion Pharmaceuticals INC. | $160.86 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $127.68 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $127.18 | 2024-2025 | Vowst, Zenpep |
| Lilly USA, LLC | $123.83 | 2021-2024 | Amyvid |
| Avanir Pharmaceuticals, INC. | $122.45 | 2019-2021 | |
| Abbott Laboratories | $107.93 | 2023-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $96.17 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $68.31 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $59.90 | 2021-2023 | Rexulti |
| Paratek Pharmaceuticals, INC. | $58.92 | 2023-2024 | Nuzyra |
| Sumitomo Pharma America, INC. | $46.66 | 2023 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $42.57 | 2020-2021 | |
| Ucb, INC. | $42.01 | 2019 | |
| Cmp Pharma, INC. | $38.56 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $37.26 | 2022-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.77 | 2023-2025 | Xifaxan, Trulance |
| Alnylam Pharmaceuticals INC. | $33.27 | 2019 | |
| Melinta Therapeutics, LLC | $32.89 | 2019 | |
| Shield Therapeutics INC | $27.64 | 2023 | Accrufer |
| Astellas Pharma US INC | $18.61 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $16.58 | 2025 | Voquezna |
| Eisai INC. | $16.02 | 2020 | |
| Urovant Sciences INC | $15.42 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.36 | 2022 | |
| Kci USA, INC. | $14.24 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evgueni Roudachevski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.